NYSEAMERICAN:CRMD CorMedix Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.15 -0.08 (-1.53 %) (As of 09/25/2020 01:00 PM ET) Add Compare Share Today's Range$5.13Now: $5.15▼$5.2850-Day Range N/A52-Week Range$2.16Now: $5.15▼$7.97Volume2,367 shsAverage Volume344,902 shsMarket Capitalization$160.88 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCorMedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, CorMedix has a forecasted upside of 169.7% from its current price of $5.19.Amount of Analyst CoverageCorMedix has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCorMedix has received 299 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCorMedix has received 292 “underperform” votes. (Add your “underperform” vote.)Community SentimentCorMedix has received 50.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote “Outperform” if you believe CRMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $392,769.00 in company stock and sold $0.00 in company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.80 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:CRMD Previous SymbolNYSEMKT:CRMD CUSIPN/A CIK1410098 Webwww.cormedix.com Phone+1-908-5179500Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees22 Outstanding Shares31,239,000Market Cap$160.88 million Next Earnings Date11/12/2020 (Estimated) OptionableOptionable $5.15 -0.08 (-1.53 %) (As of 09/25/2020 01:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CRMD News and Ratings via Email Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of CorMedix? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CorMedix. When is CorMedix's next earnings date? CorMedix is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for CorMedix. How were CorMedix's earnings last quarter? CorMedix Inc. (NYSEAMERICAN:CRMD) announced its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.14) EPS for the quarter, topping the Zacks' consensus estimate of ($0.24) by $0.10. The biotechnology company earned $0.02 million during the quarter, compared to the consensus estimate of $0.10 million. View CorMedix's earnings history. When did CorMedix's stock split? How did CorMedix's stock split work? CorMedix's stock reverse split before market open on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split. What price target have analysts set for CRMD? 3 brokers have issued 1-year price objectives for CorMedix's shares. Their forecasts range from $10.00 to $20.00. On average, they anticipate CorMedix's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 171.8% from the stock's current price. View analysts' price targets for CorMedix. Are investors shorting CorMedix? CorMedix saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 3,640,000 shares, an increase of 15.2% from the July 30th total of 3,160,000 shares. Based on an average daily trading volume, of 379,100 shares, the short-interest ratio is presently 9.6 days. View CorMedix's Short Interest. Who are some of CorMedix's key competitors? Some companies that are related to CorMedix include Aptose Biosciences (APS), SIGA Technologies (SIGA), Biotest (BIO), CEL-SCI (CVM), Inventiva (IVA), Pfenex (PFNX), Pfenex (PFNX), Altimmune (ALT), iShares Diversified Alternatives Trust (ALT), IMV (IMV), Ergomed (ERGO), Silence Therapeutics (SLN), Ibio (IBIO), Neptune Wellness Solutions (NEPT) and ProMetic Life Sciences (PLI). View all competitors. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include ZIOPHARM Oncology (ZIOP), Rexahn Pharmaceuticals (REXN), Amarin (AMRN), Precigen (PGEN), AcelRx Pharmaceuticals (ACRX), Kindred Biosciences (KIN), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Opko Health (OPK) and Advanced Micro Devices (AMD). Who are CorMedix's key executives? CorMedix's management team includes the following people: Mr. Khoso Baluch, CEO & Director (Age 61)Mr. Robert W. Cook, Chief Financial Officer (Age 63)Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 75)Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 40)Dr. Phoebe Mounts, Exec. VP & Gen. Counsel What is CorMedix's stock symbol? CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD." Who are CorMedix's major shareholders? CorMedix's stock is owned by many different institutional and retail investors. Top institutional investors include Nuveen Asset Management LLC (0.39%), Steward Partners Investment Advisory LLC (0.31%), Charles Schwab Investment Management Inc. (0.20%), California Public Employees Retirement System (0.20%), Planning Directions Inc. (0.19%) and Bank of America Corp DE (0.09%). Company insiders that own CorMedix stock include Alan W Dunton, Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook and Steven W Lefkowitz. View institutional ownership trends for CorMedix. Which institutional investors are selling CorMedix stock? CRMD stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, and UBS Group AG. View insider buying and selling activity for CorMedix. Which institutional investors are buying CorMedix stock? CRMD stock was purchased by a variety of institutional investors in the last quarter, including Planning Directions Inc., California Public Employees Retirement System, SG Americas Securities LLC, Two Sigma Advisers LP, Bank of America Corp DE, Jacobs Levy Equity Management Inc., State Board of Administration of Florida Retirement System, and Avestar Capital LLC. Company insiders that have bought CorMedix stock in the last two years include Alan W Dunton, Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook, and Steven W Lefkowitz. View insider buying and selling activity for CorMedix. How do I buy shares of CorMedix? Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CorMedix's stock price today? One share of CRMD stock can currently be purchased for approximately $5.15. How big of a company is CorMedix? CorMedix has a market capitalization of $160.88 million. CorMedix employs 22 workers across the globe. What is CorMedix's official website? The official website for CorMedix is www.cormedix.com. How can I contact CorMedix? CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500. This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
